Holen Sie sich die Stockscreener-App
2.93
1.74%
0.05
Vorhandelsmarkt:
2.86
-0.07
-2.39%
Schlusskurs vom Vortag:
$2.88
Offen:
$2.86
24-Stunden-Volumen:
90,593
Relative Volume:
0.60
Marktkapitalisierung:
$98.24M
Einnahmen:
$210.00K
Nettoeinkommen (Verlust:
$-10.40M
KGV:
-9.3045
EPS:
-0.3149
Netto-Cashflow:
$-6.88M
1W Leistung:
+7.33%
1M Leistung:
+3.53%
6M Leistung:
-34.45%
1J Leistung:
+2.81%
1-Tages-Spanne:
$2.785
$2.93
1-Wochen-Bereich:
$2.6197
$2.93
52-Wochen-Spanne:
$2.44
$5.4566
Anixa Biosciences Inc Stock (ANIX) Company Profile
Firmenname
Anixa Biosciences Inc
Sektor
Branche
Telefon
408-708-9808
Adresse
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Compare ANIX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
2.93 | 98.24M | 210.00K | -10.40M | -6.88M | -0.3149 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 112.35B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.71B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 52.29B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 44.48B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 35.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-21 | Eingeleitet | Maxim Group | Buy |
| 2022-12-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2021-04-12 | Eingeleitet | H.C. Wainwright | Buy |
Anixa Biosciences Inc Aktie (ANIX) Neueste Nachrichten
Anixa Biosciences Highlights Lean Cash Burn, CAR-T Survival Signals, and Phase II Vaccine Plan at Conference - Yahoo Finance
Weekly Trades: Does Anixa Biosciences Inc have declining or rising EPS2026 Reactions & Daily Profit Maximizing Tips - baoquankhu1.vn
Aug Macro: Can Anixa Biosciences Inc maintain its current growth rate2026 Analyst Calls & Consistent Profit Trade Alerts - baoquankhu1.vn
AVAX Technologies and Anixa Biosciences Compared in Critical Analysis - National Today
Earnings Risk: Does Anixa Biosciences Inc have declining or rising EPSWeekly Trend Recap & Daily Growth Stock Investment Tips - baoquankhu1.vn
Anixa Biosciences Reports Positive Clinical Trial Results for Cancer Vaccines - Intellectia AI
Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026 - Finviz
At April 16 event, Anixa will spotlight 74% immune response data - Stock Titan
Anixa Biosciences Price Target Maintained With a $10.00/Share by D. Boral Capital - Moomoo
ANIX Stock: Consistent 'Buy' Rating and Price Target Maintained - GuruFocus
Anixa Biosciences' (ANIX) "Buy" Rating Reiterated at D. Boral Capital - MarketBeat
Anixa Biosciences to Present at Water Tower Research Insights Conference - National Today
Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026 - PR Newswire
74% vaccine response, CAR-T survival data on Anixa's April 14 agenda - Stock Titan
Breast cancer vaccine hit Phase 1 goals; Anixa cites CAR-T survival data - Stock Titan
Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs - Barchart.com
Anixa Biosciences (NASDAQ:ANIX) Stock Rating Lowered by Wall Street Zen - MarketBeat
Anixa partners with Cytovance for breast cancer vaccine trial By Investing.com - Investing.com South Africa
ANIX Stock Price, Quote & Chart | ANIXA BIOSCIENCES INC (NASDAQ:ANIX) - ChartMill
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing - Sahm
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 - GuruFocus
Anixa Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results - Oncodaily
Eli Lilly, Space stocks, Anixa Biosciences - TradingView — Track All Markets
Anixa Biosciences (ANIX) Advances Breast Cancer Vaccine with New Manufacturing Agreement - GuruFocus
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 with Selection of Cytovance Biologics for cGMP Manufacturing - irw-press.com
Anixa partners with Cytovance for breast cancer vaccine trial - Investing.com
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results Cytovance Selected For Cgmp Manufacturing - TradingView
Anixa Biosciences, Inc. (ANIX) Stock Price, News, Quote & History - Yahoo Finance
ANIX: Anixa Biosciences Retains 'Buy' Rating with Price Target U - GuruFocus
Anixa Biosciences, Inc. (ANIX) Options Chain - Yahoo! Finance Canada
Anixa Biosciences (NASDAQ:ANIX) Given Buy Rating at D. Boral Capital - MarketBeat
Anixa Biosciences to Present Ovarian Cancer CAR-T Therapy Trial at Gynecologic Oncology Conference - National Today
Anixa Biosciences Advances Cancer Therapy with Lira-cel Trial Update - Intellectia AI
Doctors will get a Phase 1 update on Anixa's ovarian cancer CAR-T - Stock Titan
Anixa Biosciences announces that clinical trial results for its CAR-T therapy targeting ovarian cancer will be officially released at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer. - Bitget
Anixa Biosciences, Inc.Common Stock (NQ: ANIX - The Chronicle-Journal
Investment Review: Can Anixa Biosciences Inc keep up with sector leaders2026 Fed Impact & Stock Market Timing Techniques - baoquankhu1.vn
Earnings Recap: Whats the beta of Anixa Biosciences Inc stockPortfolio Performance Report & Technical Pattern Based Buy Signals - baoquankhu1.vn
We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate - Sahm
Anixa Biosciences (NASDAQ:ANIX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Exclusive: Anixa Biosciences' ovarian cancer drug candidate shows longer survival with no major safety issues - MSN
Anixa Biosciences (NASDAQ:ANIX) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Anixa Biosciences AGM: Shareholders Back Directors as CEO Highlights CAR-T, Vaccine Progress - MarketBeat
Can Anixa Biosciences Inc keep up with sector leadersTrade Risk Assessment & Verified Stock Trade Ideas - baoquankhu1.vn
Anixa Biosciences Featured on Water Tower Research Healthcare Ha - GuruFocus
Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast - PR Newswire
Experimental breast cancer vaccine shows positive data, Anixa CEO says - Stock Titan
Anixa Biosciences Shareholders Back Board and Compensation - TipRanks
Anixa Biosciences (NASDAQ: ANIX) investors approve directors, pay and auditor - Stock Titan
Anixa Biosciences Inc. Q1 2026 Financial Report: Earnings, Balance Sheet, and Key Disclosures - Minichart
Finanzdaten der Anixa Biosciences Inc-Aktie (ANIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Anixa Biosciences Inc-Aktie (ANIX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Titterton Lewis H jr | Director |
Dec 15 '25 |
Option Exercise |
2.92 |
16,000 |
46,720 |
969,334 |
| KUMAR AMIT | Chief Executive Officer |
Oct 30 '25 |
Option Exercise |
2.92 |
200,000 |
584,000 |
779,925 |
| Titterton Lewis H jr | Director |
Jul 31 '25 |
Buy |
3.08 |
10,000 |
30,800 |
953,334 |
| KUMAR AMIT | Chief Executive Officer |
Jul 30 '25 |
Buy |
3.16 |
5,000 |
15,800 |
579,925 |
| Baskies Arnold M | Director |
Jul 18 '25 |
Buy |
3.39 |
5,000 |
16,950 |
125,000 |
| Titterton Lewis H jr | Director |
Jul 11 '25 |
Buy |
3.14 |
10,000 |
31,400 |
943,334 |
| KUMAR AMIT | Chief Executive Officer |
Jul 11 '25 |
Buy |
3.15 |
5,000 |
15,750 |
574,925 |
| KUMAR AMIT | Chief Executive Officer |
Jun 04 '25 |
Buy |
2.85 |
10,000 |
28,500 |
569,925 |
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):